M N Thomas1, G H Sauter2,3, A L Gerbes2,3, M Stangl4, T S Schiergens4, M Angele4, J Werner4, M Guba4,3. 1. Department of General, Visceral, Transplantation, Vascular and Thoracic Surgery, L.M., University of Munich, Campus Großhadern, Marchioninistrasse 15, 81375, München, Deutschland, Germany. michael.thomas@med.uni-muenchen.de. 2. Department of Medicine II, Klinikum Großhadern, L.M., University of Munich, Munich, Germany. 3. Liver Center Munich, Klinikum Großhadern, L.M., University of Munich, Munich, Germany. 4. Department of General, Visceral, Transplantation, Vascular and Thoracic Surgery, L.M., University of Munich, Campus Großhadern, Marchioninistrasse 15, 81375, München, Deutschland, Germany.
Abstract
INTRODUCTION: Ascites is a common complication of liver cirrhosis and represents the main cause of hospitalization among patients with cirrhosis. First-line therapy for those patients is the use of diuretics and dietary sodium restriction. However, 10 % of patients per year become therapy refractory to diuretic treatment with the need of repeated high-volume paracentesis or transjugular intrahepatic portosystemic shunt (TIPS). For these patients, an automated pump system (Alfapump/Sequana Medical) was developed. Here, we describe our single-center experience of ten consecutively implanted pump systems. PATIENTS AND METHODS: Between 08/13 and 11/14, ten Alfapump systems were implanted in patients with refractory ascites all suffering from liver cirrhosis. Those patients were treated as a bridge to transplant (4/10) or as an end-stage therapy (6/10). Median follow-up was 165 days (23-379 days). RESULTS: Postimplant, the need of paracentesis could be markedly reduced to a mean of 0.45 (0-4/month) per month. In eight patients, paracentesis was not needed after implantation of the pump system. The median daily output volume was 1000 ml/day (450-2000 ml/day). Prerenal insufficiency was a recurrent complication in the postoperative period. DISCUSSION: The Alfapump system is a useful system in the treatment of patients suffering from therapy refractory ascites. However, due to the high level of comorbidities, careful patient selection and postoperative monitoring are required.
INTRODUCTION:Ascites is a common complication of liver cirrhosis and represents the main cause of hospitalization among patients with cirrhosis. First-line therapy for those patients is the use of diuretics and dietary sodium restriction. However, 10 % of patients per year become therapy refractory to diuretic treatment with the need of repeated high-volume paracentesis or transjugular intrahepatic portosystemic shunt (TIPS). For these patients, an automated pump system (Alfapump/Sequana Medical) was developed. Here, we describe our single-center experience of ten consecutively implanted pump systems. PATIENTS AND METHODS: Between 08/13 and 11/14, ten Alfapump systems were implanted in patients with refractory ascites all suffering from liver cirrhosis. Those patients were treated as a bridge to transplant (4/10) or as an end-stage therapy (6/10). Median follow-up was 165 days (23-379 days). RESULTS: Postimplant, the need of paracentesis could be markedly reduced to a mean of 0.45 (0-4/month) per month. In eight patients, paracentesis was not needed after implantation of the pump system. The median daily output volume was 1000 ml/day (450-2000 ml/day). Prerenal insufficiency was a recurrent complication in the postoperative period. DISCUSSION: The Alfapump system is a useful system in the treatment of patients suffering from therapy refractory ascites. However, due to the high level of comorbidities, careful patient selection and postoperative monitoring are required.
Authors: Richard Moreau; Paul Delègue; Fabienne Pessione; Sophie Hillaire; François Durand; Didier Lebrec; Dominique-Charles Valla Journal: Liver Int Date: 2004-10 Impact factor: 5.828
Authors: Francesco Salerno; Monica Guevara; Mauro Bernardi; Richard Moreau; Florence Wong; Paolo Angeli; Guadalupe Garcia-Tsao; Samuel S Lee Journal: Liver Int Date: 2010-05-21 Impact factor: 5.828
Authors: V Harding; E Fenu; H Medani; R Shaboodien; S Ngan; H K Li; R Burt; N Diamantis; M Tuthill; S Blagden; H Gabra; C E Urch; S Moser; R Agarwal Journal: Br J Cancer Date: 2012-08-09 Impact factor: 7.640
Authors: J Dembinski; D Aranovich; V Banz; T Ehmann; I Klein; M Malago; N Richter; A A Schnitzbauer; W Staszewicz; H-M Tautenhahn; J Capel; J-M Regimbeau Journal: Langenbecks Arch Surg Date: 2020-01-08 Impact factor: 3.445
Authors: Delphine Weil-Verhoeven; Vincent Di Martino; Guido Stirnimann; Jean Paul Cervoni; Eric Nguyen-Khac; Thierry Thévenot Journal: World J Hepatol Date: 2022-07-27